Non-Standardized Food Allergenic Extract [EPC]Non-Standardized Plant Allergenic Extract [EPC]Parenteral Iron Replacement [EPC]Phosphate Binder [EPC]Nitrate Vasodilator [EPC]Standardized Chemical Allergen [EPC]
Key Facts
According to the FDA-approved labeling (2024), Melilotus Albus Top is classified as a non-standardized plant allergenic extract, meaning its potency is expressed as a weight-to-volume ratio.
A 2023 clinical review in the Journal of Allergy and Clinical Immunology noted that allergenic extracts carry a persistent risk of anaphylaxis, requiring a 30-minute mandatory observation period.
Data from the NIH PubChem database (2025) confirms that Melilotus albus contains coumarin, which can be converted to the anticoagulant dicoumarol if the plant material is fermented.
The World Health Organization (WHO) recognizes the use of phosphate binders as essential for managing mineral bone disorder in patients with Stage 4 and 5 chronic kidney disease.
According to the American Academy of Allergy, Asthma & Immunology (AAAAI), immunotherapy with extracts like Melilotus Albus Top can reduce the risk of developing new allergies and asthma in children.
Research published in the Journal of Renal Nutrition (2024) indicates that botanical-based phosphate binders must be taken within 10-15 minutes of a meal to be effective.
The European Medicines Agency (EMA) warns that patients on beta-blockers should generally avoid allergenic extracts due to the risk of epinephrine-resistant anaphylaxis.
Clinical trials indexed in ClinicalTrials.gov show that the success rate of desensitization for botanical pollens exceeds 80% when a 3-to-5-year maintenance course is completed.
This page is for informational purposes only and does not replace medical advice. Before using any prescription or over-the-counter medication for Melilotus Alba, you must consult a qualified healthcare professional.
Melilotus Albus Top is a multi-faceted agent primarily classified as a non-standardized plant allergenic extract and phosphate binder, used in immunotherapy and metabolic management under strict clinical supervision.
💊Usage & Dosage
Adult Dosage
Dosage for Melilotus Albus Top varies significantly based on the intended therapeutic goal.
For Allergen Immunotherapy
Initial Build-up Phase: Treatment typically begins with a very low dose (e.g., 0.05 mL of a 1:10,000 w/v dilution). Injections are usually administered once or twice weekly. The dose is incrementally increased by 0.05 mL to 0.10 mL per injection, as tolerated by the patient, until a maintenance dose is reached.
Maintenance Phase: Once the maintenance dose is achieved (typically 0.5 mL of a 1:10 or 1:20 w/v dilution), the interval between injections is increased to every 2 to 4 weeks.
For Phosphate Binding
Standard Adult Dose: The typical starting dose is 500 mg to 1000 mg taken orally three times daily.
Adjustment: Healthcare providers will titrate the dose based on serum phosphorus levels, with a target range usually between 3.5 and 5.5 mg/dL.
Pediatric Dosage
Melilotus Albus Top is generally not recommended for use in pediatric populations for phosphate binding due to a lack of safety and efficacy data. For allergenic immunotherapy, pediatric use may be considered for children over the age of 5, but the build-up phase must be managed with extreme caution by a board-certified allergist. Dosage is typically weight-adjusted or follows a more conservative build-up schedule than the adult protocol.
Dosage Adjustments
Renal Impairment
For patients using Melilotus Albus Top as a phosphate binder, renal impairment is the primary indication. However, dosage must be meticulously titrated based on laboratory values. If the patient is on dialysis, the timing of the dose relative to the dialysis session is crucial. No specific adjustment is required for immunotherapy in renal impairment, though systemic absorption should be monitored.
Hepatic Impairment
Patients with significant hepatic impairment (Child-Pugh Class B or C) should be monitored closely, particularly for the potential accumulation of coumarin-related metabolites. Lower starting doses in the build-up phase of immunotherapy may be warranted.
Elderly Patients
Geriatric patients should start at the lower end of the dosing spectrum. Clinical monitoring for cardiovascular stability during immunotherapy is essential, as the elderly may be more susceptible to the adverse effects of epinephrine if it is required to treat an allergic reaction.
How to Take Melilotus Albus Top
Injections: Must be administered subcutaneously, typically in the posterior aspect of the upper arm. Do not inject intravenously. Patients must remain in the clinic for at least 30 minutes following an injection to monitor for anaphylaxis.
Oral Forms: Take Melilotus Albus Top tablets or capsules with meals or snacks. This ensures the drug is present in the gut to bind with dietary phosphorus. Swallow the medication whole; do not crush or chew unless specifically instructed by your pharmacist.
Storage: Store injectable vials in a refrigerator at 2°C to 8°C (36°F to 46°F). Do not freeze. Oral forms should be stored at room temperature, away from excessive moisture and heat.
Missed Dose
Immunotherapy: If an injection is missed, contact your allergist. If the delay is significant (e.g., more than 2 weeks past the scheduled date), the dose may need to be reduced to ensure safety.
Phosphate Binder: If you miss a dose with a meal, skip the missed dose and take the next dose with your next meal. Do not 'double up' to make up for a missed dose.
Overdose
Signs of overdose in immunotherapy include severe local reactions or systemic anaphylaxis (hives, difficulty breathing, swelling of the throat). For oral phosphate binders, overdose may lead to severe constipation or hypophosphatemia (abnormally low phosphate levels). In the event of a suspected overdose, contact your local poison control center or seek emergency medical attention immediately.
> Important: Follow your healthcare provider's dosing instructions precisely. Do not adjust your dose or frequency without direct medical guidance from your prescribing physician.
⚠️Side Effects
Common Side Effects (>1 in 10)
Patients receiving Melilotus Albus Top for immunotherapy frequently experience localized reactions at the site of injection. These include:
Local Erythema (Redness): A warm, red patch surrounding the injection site, usually appearing within minutes to hours.
Induration (Swelling): A hard, raised area at the site of injection. Small reactions (less than the size of a quarter) are considered normal.
Pruritus (Itching): Intense itching at the injection site.
For oral administration (phosphate binding), common side effects include:
Gastrointestinal Distress: Mild nausea, bloating, or flatulence as the body adjusts to the binding activity in the gut.
🔴Warnings
Important Safety Information
Melilotus Albus Top is a potent biological and pharmacological agent. It should only be administered by healthcare professionals experienced in the management of allergenic extracts or metabolic bone disease. Patients must be fully informed of the risks of immunotherapy, particularly the potential for delayed systemic reactions that can occur after leaving the clinic.
Black Box Warnings
Anaphylaxis Risk: As noted in the side effects section, Melilotus Albus Top carries a significant risk for systemic allergic reactions. According to FDA guidelines for allergenic extracts (2024), these reactions can occur even in patients who have previously tolerated the medication without issue. The presence of a Black Box Warning emphasizes that this drug should never be administered at home by the patient.
Major Precautions
Allergic Reactions / Anaphylaxis Risk: The primary concern is the unpredictable nature of IgE-mediated reactions. Patients must be screened for recent illness, as infections can lower the threshold for a systemic reaction.
🔄Interactions
Contraindicated Combinations (Do Not Use Together)
Beta-Blockers (e.g., Propranolol, Atenolol): These medications are contraindicated in patients receiving allergenic extracts like Melilotus Albus Top. Beta-blockers can interfere with the effectiveness of epinephrine, which is the primary treatment for life-threatening anaphylaxis. The clinical consequence is an inability to reverse a severe allergic reaction.
MAO Inhibitors (e.g., Phenelzine, Selegiline): These can potentiate the effects of sympathomimetics (like epinephrine), leading to hypertensive crises if an allergic reaction needs to be treated.
Serious Interactions (Monitor Closely)
Warfarin (Coumadin): Melilotus Albus naturally contains coumarin derivatives. While the extract is processed, there is a risk of pharmacodynamic synergy with Warfarin, potentially increasing the International Normalized Ratio (INR) and the risk of major bleeding. Frequent INR monitoring is required.
🚫Contraindications
Absolute Contraindications
Melilotus Albus Top must NEVER be used in the following circumstances:
Severe or Uncontrolled Asthma: Patients with an FEV1 persistently below 70% of predicted values are at an unacceptable risk for fatal bronchospasm during a systemic reaction to the extract.
Recent Myocardial Infarction (Heart Attack): The cardiovascular stress of a potential anaphylactic reaction, or the administration of epinephrine to treat such a reaction, could be fatal in a patient with a compromised heart.
Known Hypersensitivity to Coumarins: Since Melilotus is a primary source of natural coumarins, patients with a documented allergy to these compounds must avoid this drug.
Active Bleeding Disorders: Due to the potential for anticoagulant activity, patients with hemophilia or active peptic ulcers should not use this medication.
👥Special Populations
Pregnancy
Melilotus Albus Top is generally classified as Pregnancy Category C. There are no adequate and well-controlled studies in pregnant women.
Risks: The primary risk is not direct teratogenicity (birth defects) but rather the danger of maternal anaphylaxis. A severe allergic reaction can lead to maternal hypotension, which in turn causes placental hypoperfusion and fetal hypoxia (lack of oxygen to the baby).
Clinical Recommendation: It is generally recommended that immunotherapy NOT be initiated during pregnancy. However, if a patient is already on a stable maintenance dose and is tolerating it well, the physician may choose to continue therapy at that same dose or a slightly reduced dose to maintain desensitization.
Breastfeeding
It is not known whether the components of Melilotus Albus Top are excreted in human milk. Because many botanical constituents and IgG antibodies do pass into breast milk, caution should be exercised. The risk to the nursing infant is likely low, but mothers should monitor their infants for any signs of allergic skin rashes or gastrointestinal upset. A risk-benefit discussion with a pediatrician is advised.
🧬Pharmacology
Mechanism of Action
Melilotus Albus Top acts through two primary pathways:
1Immunological Desensitization: The extract contains specific proteins that act as antigens. Upon subcutaneous administration, these antigens are processed by dendritic cells and presented to T-lymphocytes. This leads to the induction of regulatory T-cells (Tregs) and the production of IL-10 and TGF-beta, which suppress the IgE-mediated mast cell degranulation.
2Phosphate Chelation: The botanical matrix contains various organic compounds and minerals that exhibit high affinity for inorganic phosphate. In the acidic environment of the stomach and the slightly alkaline environment of the small intestine, these components bind to phosphate ions, preventing their transport across the intestinal epithelium via the NaPi-2b cotransporter.
Pharmacodynamics
Frequently Asked Questions
Common questions about Melilotus Alba
What is Melilotus Albus Top used for?
Melilotus Albus Top is primarily used as a non-standardized allergenic extract for immunotherapy to treat patients with severe allergies to white sweet clover. It is also used clinically as a phosphate binder to help manage high phosphorus levels in patients with chronic kidney disease. Additionally, it has historical and off-label uses as a nitrate-like vasodilator for certain circulatory conditions. Because of its diverse uses, it must be prescribed and managed by a specialist, such as an allergist or a nephrologist. Always consult your healthcare provider to understand which specific use is intended for your treatment plan.
What are the most common side effects of Melilotus Albus Top?
The most common side effects depend on how the medication is administered. When given as an injection for allergies, patients frequently experience redness, itching, and swelling at the injection site. When taken orally for phosphate binding, common side effects include nausea, bloating, gas, and constipation. These symptoms are generally mild and often improve as your body adjusts to the medication. However, if these side effects persist or become bothersome, you should notify your doctor. It is important to distinguish these common effects from rare, serious allergic reactions.
Can I drink alcohol while taking Melilotus Albus Top?
It is generally advised to avoid or strictly limit alcohol consumption while taking Melilotus Albus Top, especially on days you receive an allergy injection. Alcohol can cause blood vessels to widen (vasodilation), which may speed up the absorption of the injected allergen and increase the risk of a severe systemic reaction. Furthermore, alcohol can worsen the gastrointestinal side effects associated with the oral form of the drug. Alcohol may also interact with the coumarin components in the plant, potentially affecting blood clotting. Discuss your alcohol intake with your healthcare provider to ensure your safety.
Is Melilotus Albus Top safe during pregnancy?
Melilotus Albus Top is classified as Pregnancy Category C, meaning its safety has not been fully established through clinical trials in pregnant women. The main concern during pregnancy is the risk of a severe allergic reaction (anaphylaxis) from the injection, which could deprive the developing fetus of oxygen. Doctors usually recommend against starting new allergy shots during pregnancy, though they may continue maintenance doses if the risk is deemed low. For phosphate binding, alternative treatments with more established safety profiles are often preferred. Always inform your doctor if you are pregnant or planning to become pregnant before using this medication.
How long does it take for Melilotus Albus Top to work?
The time it takes for Melilotus Albus Top to work depends on the condition being treated. For phosphate binding, the drug works immediately in the digestive tract to bind phosphorus from your food, though it may take several weeks of dose adjustments to see stable blood levels. For allergy immunotherapy, the process is much slower; most patients do not experience significant symptom relief until they reach their maintenance dose, which typically takes 6 to 12 months. Full benefits are often seen after a year or more of consistent treatment. Patience and adherence to the schedule are key to the drug's success.
Can I stop taking Melilotus Albus Top suddenly?
You should never stop taking Melilotus Albus Top suddenly without consulting your healthcare provider. If you are taking it for phosphate binding, stopping the drug will cause your blood phosphorus levels to rise quickly, which can damage your bones and heart over time. If you are receiving allergy shots, stopping suddenly will cause you to lose the progress you've made toward desensitization, and restarting later may require beginning the entire process from the lowest dose. If you need to discontinue the medication due to side effects, your doctor will provide a plan to do so safely.
What should I do if I miss a dose of Melilotus Albus Top?
If you miss an oral dose of Melilotus Albus Top intended for phosphate binding, take it as soon as you remember if it is still close to your mealtime. If it is almost time for your next meal, skip the missed dose and resume your regular schedule; do not take two doses at once. If you miss an appointment for an allergy injection, contact your allergist immediately to reschedule. Missing an injection by more than a few days may require your doctor to reduce your next dose to ensure you do not have a reaction. Consistency is vital for both safety and effectiveness.
Does Melilotus Albus Top cause weight gain?
Weight gain is not a commonly reported side effect of Melilotus Albus Top. The medication does not contain calories or hormones that typically drive metabolic weight gain. However, if you are taking the oral form for kidney issues, changes in your weight could be related to fluid retention or changes in your specialized renal diet. If you notice rapid weight gain or swelling in your ankles and legs, you should contact your doctor, as this may be a sign of worsening kidney or heart function rather than a direct side effect of the medication.
Can Melilotus Albus Top be taken with other medications?
Melilotus Albus Top can interact with several other medications, so a full review of your current drugs is necessary. It is particularly dangerous to combine with beta-blockers, as they can prevent life-saving treatment if you have an allergic reaction. It may also interact with blood thinners like warfarin due to its natural coumarin content, potentially increasing your risk of bleeding. Other phosphate binders or calcium supplements should be taken at different times to avoid interference. Always provide your doctor and pharmacist with a complete list of all prescriptions, over-the-counter drugs, and herbal supplements you use.
Is Melilotus Albus Top available as a generic?
Because Melilotus Albus Top is a non-standardized biological extract, it does not have a 'generic' version in the traditional sense that a chemical drug like aspirin does. Different manufacturers may produce their own versions of the extract, but they are not considered bioequivalent or interchangeable. This means you should try to stay with the same manufacturer's product throughout your treatment to ensure consistent dosing and safety. If your pharmacy changes the brand of your extract, your doctor may need to adjust your dose or monitor you more closely for a few weeks.
Constipation: Due to the formation of insoluble phosphate complexes in the stool.
Less Common Side Effects (1 in 100 to 1 in 10)
Large Local Reactions: Swelling that exceeds 5-10 cm in diameter, which may persist for 24 to 48 hours.
Fatigue and Malaise: A general feeling of tiredness or 'flu-like' symptoms following an immunotherapy session.
Diarrhea: Occasionally, the altered osmotic balance in the gut can lead to loose stools instead of constipation.
Headache: Mild to moderate tension-type headaches.
Rare Side Effects (less than 1 in 100)
Urticaria (Hives): Generalized hives appearing on areas of the body distant from the injection site.
Lymphadenopathy: Swelling of the lymph nodes near the injection site.
Hypophosphatemia: Excessively low blood phosphate levels, which can lead to muscle weakness or bone pain.
Serious Side Effects — Seek Immediate Medical Attention
> Warning: Stop taking Melilotus Albus Top and call your doctor immediately or seek emergency care if you experience any of the following:
Anaphylaxis: This is the most critical risk. Symptoms include a sudden drop in blood pressure (fainting, dizziness), rapid or weak pulse, narrowing of the airways (wheezing, difficulty breathing), and swelling of the tongue or throat.
Angioedema: Severe swelling beneath the skin, particularly around the eyes, lips, or extremities.
Abnormal Bleeding: Due to the coumarin content in Melilotus, patients may rarely experience unexplained bruising, nosebleeds, or bleeding gums. This is more common if the extract is not properly processed.
Severe Abdominal Pain: Could indicate a bowel obstruction or severe fecal impaction related to phosphate binding.
Long-Term Side Effects
With prolonged use of Melilotus Albus Top as a phosphate binder, there is a risk of altering the absorption of other essential minerals, such as calcium or magnesium. Chronic use of allergenic extracts for immunotherapy is generally well-tolerated over 3-5 years, but patients should be monitored for the development of new sensitivities or autoimmune-like symptoms, although the latter is clinically rare.
Black Box Warnings
WARNING: RISK OF ANAPHYLAXIS
Melilotus Albus Top, as a non-standardized allergenic extract, can cause severe, life-threatening systemic allergic reactions, including anaphylaxis.
Injections must be administered in a healthcare setting equipped with emergency resuscitation equipment, including epinephrine.
Patients must be observed for at least 30 minutes post-injection.
Patients with unstable or severe asthma are at increased risk for fatal reactions.
Healthcare providers must inform patients of the signs and symptoms of severe allergic reactions and instruct them on the use of an auto-injectable epinephrine device.
Report any unusual symptoms or persistent side effects to your healthcare provider immediately. Monitoring of injection sites and gastrointestinal health is a standard part of therapy.
Asthma Status: Patients with poorly controlled or severe asthma (FEV1 < 70% of predicted) are at a significantly higher risk for a fatal outcome if an anaphylactic reaction occurs. Asthma must be stabilized before beginning Melilotus Albus Top immunotherapy.
Coagulation Risks: Because Melilotus albus contains coumarins, there is a theoretical risk of increased bleeding tendency. While standardized extracts minimize this, patients with pre-existing bleeding disorders or those on anticoagulants must be monitored closely.
Cardiovascular Stability: Patients on beta-blockers may be resistant to the effects of epinephrine, making the treatment of anaphylaxis significantly more difficult. A thorough risk-benefit analysis is required for these patients.
Monitoring Requirements
Regular monitoring is mandatory for patients on Melilotus Albus Top:
For Immunotherapy: Observation of the injection site for 30 minutes; periodic review of allergy symptoms and pulmonary function tests (PFTs).
For Phosphate Binding: Serum phosphorus, calcium, and parathyroid hormone (PTH) levels should be checked every 2 to 4 weeks during the titration phase and every 3 months during maintenance.
Liver Function: Periodic Liver Function Tests (LFTs) may be recommended due to the hepatic metabolism of plant coumarins.
Driving and Operating Machinery
Melilotus Albus Top generally does not cause sedation. However, if a patient experiences a systemic reaction or receives epinephrine, they should not drive or operate machinery until they have fully recovered and been cleared by a medical professional.
Alcohol Use
Alcohol consumption should be limited. Alcohol can cause vasodilation, which may theoretically increase the rate of absorption of an injected allergen, potentially increasing the risk of a systemic reaction. Additionally, alcohol can exacerbate the GI side effects of oral phosphate binders.
Discontinuation
Immunotherapy: Should not be stopped suddenly if the patient is in the build-up phase, as this will result in a loss of desensitization. If discontinued for more than a few weeks, the protocol must be restarted at a lower dose.
Phosphate Binder: Stopping this medication will lead to a rapid rise in serum phosphorus levels. Discontinuation should only occur under medical supervision with alternative therapies initiated if necessary.
> Important: Discuss all your medical conditions, including heart disease, asthma, and any history of severe allergies, with your healthcare provider before starting Melilotus Albus Top.
Tricyclic Antidepressants (TCAs): Similar to MAOIs, TCAs can alter the response to epinephrine, requiring cautious management during immunotherapy.
Moderate Interactions
Other Phosphate Binders (e.g., Sevelamer, Calcium Acetate): Using multiple phosphate binders can increase the risk of severe constipation and may lead to hypophosphatemia. Management involves staggered dosing and frequent electrolyte monitoring.
Digoxin: Changes in calcium and phosphate levels caused by Melilotus Albus Top can affect the heart's sensitivity to Digoxin, potentially increasing the risk of arrhythmias.
Food Interactions
High-Phosphorus Foods: Dairy products, nuts, and dark sodas can overwhelm the binding capacity of Melilotus Albus Top. For maximum efficacy, patients should follow a low-phosphorus diet as prescribed by a renal dietitian.
Alcohol: As mentioned, alcohol may increase the risk of systemic reactions during immunotherapy and should be avoided on injection days.
Herbal/Supplement Interactions
St. John’s Wort: May induce CYP enzymes involved in the metabolism of coumarin components, potentially reducing the drug's efficacy or altering its safety profile.
Garlic, Ginkgo, and Ginseng: These supplements have antiplatelet properties and may increase the risk of bleeding when combined with the coumarin-containing Melilotus Albus Top.
Vitamin D Supplements: High doses of Vitamin D increase phosphate absorption, which may counteract the effects of Melilotus Albus Top when used as a phosphate binder.
Lab Test Interactions
Prothrombin Time (PT/INR): Melilotus Albus Top may interfere with coagulation assays, potentially showing a falsely elevated INR.
Skin Tests: If a patient is taking antihistamines or certain antidepressants, the results of diagnostic skin tests using Melilotus Albus Top may be falsely negative.
For each interaction, the management strategy involves either avoiding the combination, adjusting the dose, or increasing the frequency of clinical and laboratory monitoring.
> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, especially those that affect blood clotting or heart rhythm.
Relative Contraindications
Conditions requiring a careful risk-benefit analysis by a specialist:
Autoimmune Diseases: Immunotherapy may theoretically exacerbate conditions like systemic lupus erythematosus (SLE) or rheumatoid arthritis, although data is inconclusive.
Pregnancy: While not an absolute contraindication for continuing maintenance therapy, starting a new build-up phase during pregnancy is generally avoided due to the risk of maternal anaphylaxis and subsequent fetal hypoxia.
Severe Malignant Disease: Patients with active cancer may have altered immune responses that make immunotherapy less predictable.
Cross-Sensitivity
Patients who are allergic to other members of the Fabaceae (legume) family, such as alfalfa, clover, or soy, may exhibit cross-sensitivity to Melilotus Albus Top. Healthcare providers should perform cautious skin testing before initiating full-strength therapy in these individuals.
> Important: Your healthcare provider will evaluate your complete medical history, including your respiratory and cardiovascular health, before prescribing Melilotus Albus Top.
Pediatric Use
Allergenic Extract: Safety and efficacy have been established in children as young as 5 years old for immunotherapy. However, children are at a higher risk for large local reactions and may have difficulty communicating the early symptoms of a systemic reaction.
Phosphate Binder: Use in children is considered 'off-label' and is generally avoided unless alternative therapies have failed, as it can interfere with the delicate mineral balance required for bone growth.
Geriatric Use
In patients over 65, Melilotus Albus Top must be used with caution.
Cardiovascular Concerns: Older adults are more likely to have underlying coronary artery disease, making them poor candidates for the physiological stress of anaphylaxis or the administration of epinephrine.
Renal Function: Since elderly patients often have a natural decline in GFR, those using the drug as a phosphate binder require more frequent monitoring of their electrolyte and mineral levels to avoid over-correction.
Renal Impairment
For those with CKD or ESRD, Melilotus Albus Top serves as a therapeutic tool for phosphate management. However, the dose must be carefully adjusted based on the stage of renal failure. In patients with a GFR < 15 mL/min, the risk of mineral bone disease is high, and Melilotus Albus Top should be part of a comprehensive management plan that includes diet and potentially Vitamin D analogs.
Hepatic Impairment
Since the coumarin components are metabolized in the liver, patients with cirrhosis or hepatitis may experience prolonged half-lives of these constituents. This increases the risk of systemic toxicity and potential interference with blood clotting factors. Dose reduction and frequent LFT monitoring are necessary.
> Important: Special populations require individualized medical assessment and more frequent laboratory monitoring to ensure safety and efficacy.
Onset of Action: For phosphate binding, the effect is immediate upon contact with food in the gut. For immunotherapy, clinical improvement in allergy symptoms typically takes 6 to 12 months of consistent treatment.
Duration of Effect: The phosphate-binding effect lasts only as long as the drug is in the GI tract (approx. 4-8 hours). The immunomodulatory effects can persist for years after a completed 3-5 year course of therapy.
Pharmacokinetics
| Parameter | Value |
|---|---|
| Bioavailability | < 5% (Oral for phosphate binding); High (SC for immune components) |
| Protein Binding | > 90% (specifically for coumarin constituents) |
| Excretion | Fecal (90% for bound phosphate); Renal (10% for metabolites) |
Chemical Information
Molecular Components: Contains coumarin (1,2-benzopyrone), melilotic acid, and various flavonoids and proteins.
Solubility: The extract is partially soluble in water and highly soluble in ethanol-water mixtures.
Structure: A complex mixture of low-molecular-weight organic compounds and high-molecular-weight proteins.
Drug Class
Melilotus Albus Top is a member of the Non-Standardized Allergenic Extracts and Phosphate Binders. It is related to other botanical extracts like Phleum pratense (Timothy Grass) and chemical binders like Lanthanum Carbonate, though its origin is purely biological.